Opexa Collaborates with Merck Serono and 4 Stocks at 52-Week Highs

Opexa Therapeutics (NASDAQ:OPXA): Closing price $3.15

Opexa reached an agreement with Merck Serono, a unit of Merck for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients with multiple sclerosis. Tcelna is being developed by Opexa and currently is in a Phase IIb clinical trial in patients suffering from Secondary Progressive MS. Potential payments to Opexa from the option and license agreement could amount to $225 million, based upon the successful development and commercialization of Tcelna for MS. Shares closed up 160.33 percent on the day at $3.15, and have been traded in a 52-week range of $1.07 to $4.60.